Advanced search
Start date
Betweenand

Morphological and phenotypic characterization of the canine prostatic carcinoma cells origin

Grant number: 19/00497-9
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): May 01, 2019
Effective date (End): April 30, 2020
Field of knowledge:Agronomical Sciences - Veterinary Medicine
Principal Investigator:Carlos Eduardo Fonseca Alves
Grantee:Giovana de Godoy Fernandes
Home Institution: Faculdade de Medicina Veterinária e Zootecnia (FMVZ). Universidade Estadual Paulista (UNESP). Campus de Botucatu. Botucatu , SP, Brazil

Abstract

Prostatic carcinoma (PC) in dogs represents a good model for comparative studies of this neoplasm in humans, and the dog is the only mammal that develops PC with high frequency. Currently, there is a debate regarding the origin of PC in dogs (urothelial versus luminal). This occurs due the similar pattern of some lesions or the high degree of differentiation of PC (impossible to define origin). As the dog is a comparative model for human PC, the definition of the tumor origin is essential for establishing this model, since in humans the origin of this tumor is predominantly luminal (adenocarcinomas). Already in dogs, urothelial and luminal tumors appear to have an equivalent frequency (excluding undifferentiated tumors, where the origin can not be determined). In humans, normal luminal cells express PSA, NKX3.1 and androgen (AR) receptors. The basal cells express high molecular weight cytokeratin and p63. On the other hand, transitional cells, which are present in the prostatic excretory ducts and urethra, are positively stained for uroplakin-III (UPIII) and GATA3. Thus, PCs in humans express PSA, NKX3.1, and AR are negative for UPIII and GATA3. On the other hand, prostatic carcinomas of urothelial origin express UPIII and/or GATA3. In dogs, there is no information on these proteins as potential diagnostic markers in canine PC. Thus, this study aimed to characterize the canine prostatic carcinoma morphologically and by immunohistochemistry to identify the cell of origin of these tumors.